Literature DB >> 21073901

Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection.

Yik Chun Wong1, Leon C W Lin, Carolina R Melo-Silva, Stewart A Smith, David C Tscharke.   

Abstract

Recombinant poxviruses are important tools for research and some are candidate vaccines. To make these viruses a simple, small vector that can be used to engineer multiple strains of vaccinia virus and other model poxviruses, including ectromelia virus is of value. Here a set of plasmids and methods for making these viruses that uses an enhanced green fluorescent protein-blasticidin resistance (GFP-bsd) fusion gene as a transient selectable marker are described. This gene is smaller than any of the bi-functional selection markers used previously. The versatility of the method across different poxviruses is demonstrated by engineering changes into multiple loci of the WR and Modified Vaccinia Ankara (MVA) strains of vaccinia virus and also ectromelia virus. Finally, a set of vaccinia virus sequences for directing homologous recombination that are very highly conserved was designed and tested. These sequences allow a single plasmid to be used to insert a transgene into multiple strains of the virus.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21073901     DOI: 10.1016/j.jviromet.2010.11.003

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  18 in total

1.  The ectromelia virus SPI-2 protein causes lethal mousepox by preventing NK cell responses.

Authors:  Carolina R Melo-Silva; David C Tscharke; Mario Lobigs; Aulikki Koskinen; Yik Chun Wong; R Mark Buller; Arno Müllbacher; Matthias Regner
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

2.  Use of a negative selectable marker for rapid selection of recombinant vaccinia virus.

Authors:  Stacy D White; Kip Conwell; Jeffrey O Langland; Bertram L Jacobs
Journal:  Biotechniques       Date:  2011-05       Impact factor: 1.993

3.  Selection of Vaccinia Virus Recombinants Using CRISPR/Cas9.

Authors:  Anjali Gowripalan; Stewart A Smith; David C Tscharke
Journal:  Bio Protoc       Date:  2021-12-20

4.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019

5.  Systemic toll-like receptor ligation and selective killing of dendritic cell subsets fail to dissect priming pathways for anti-vaccinia virus CD8⁺ T cells.

Authors:  Yik Chun Wong; Stewart A Smith; David C Tscharke
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

6.  Methodology for the efficient generation of fluorescently tagged vaccinia virus proteins.

Authors:  N Bishara Marzook; Dean J Procter; Helena Lynn; Yui Yamamoto; Jacquelyn Horsington; Timothy P Newsome
Journal:  J Vis Exp       Date:  2014-01-17       Impact factor: 1.355

7.  Reverse Engineering Field Isolates of Myxoma Virus Demonstrates that Some Gene Disruptions or Losses of Function Do Not Explain Virulence Changes Observed in the Field.

Authors:  June Liu; Isabella M Cattadori; Derek G Sim; John-Sebastian Eden; Edward C Holmes; Andrew F Read; Peter J Kerr
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

8.  Strikingly poor CD8+ T-cell immunogenicity of vaccinia virus strain MVA in BALB/c mice.

Authors:  Tiffany A Russell; David C Tscharke
Journal:  Immunol Cell Biol       Date:  2014-02-25       Impact factor: 5.126

9.  Direct Priming of CD8+ T Cells Persists in the Face of Cowpox Virus Inhibitors of Antigen Presentation.

Authors:  Leon C W Lin; Sarah N Croft; Nathan P Croft; Yik Chun Wong; Stewart A Smith; Swee-Seong Tang; Anthony W Purcell; David C Tscharke
Journal:  J Virol       Date:  2021-03-10       Impact factor: 5.103

10.  Transformation of sexually transmitted infection-causing serovars of chlamydia trachomatis using Blasticidin for selection.

Authors:  Honglei Ding; Siqi Gong; Yingxin Tian; Zhangsheng Yang; Robert Brunham; Guangming Zhong
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.